24 results about "Tissue remodeling" patented technology

The application discloses a fish scale protein polypeptide anti-chronic heart failure efficacy evaluation system, relates to the technical field of biological active polypeptide evaluation and cardiovascular disease function analysis, and comprises a raw material processing module for preparing fish scale protein polypeptides, a CHF model construction module for animal experiments, a function detection module, and a data processing and analysis module. Multidimensional statistics and visual algorithm are adopted to integrate tissue remodeling indexes such as heart function, oxidative stress and inflammatory reaction, so that comprehensive evaluation of the efficacy of fish scale protein polypeptides is realized. The application can realize systematic, quantitative and mechanistic evaluation of the anti-chronic heart failure effect of fish scale protein polypeptides, solve the problems of single evaluation index, poor repeatability of results and lack of mechanism correlation in the prior art, and has the advantages of comprehensive evaluation, reliable results, wide application range and strong generalizability.

A tendon repair implant for treatment of a partial thickness tear in the supraspinatus tendon of the shoulder is provided. The implant may incorporate features of rapid deployment and fixation by an arthroscopic means approach that compliment current procedures; tensile properties that result in desired sharing of anatomical load between the implant and native tendon during rehabilitation; selected porosity and longitudinal pathways for tissue in-growth; sufficient cyclic straining of the implant in the longitudinal direction to promote remodeling of new tissue to tendon-like tissue; and, may include a bioresorbable construction to provide transfer of additional load to new tendon-like tissue and native tendon over time.

The present application relates to the technical field of biomedical materials, in particular to a composite gel containing core-shell structure calcium hydroxyapatite microspheres, a preparation method and application thereof. The composite gel comprises a gel carrier and microspheres dispersed in the gel carrier, the microspheres comprise a core and a shell layer coated on the outside of the core, the core is a biodegradable polymer, and the shell layer is calcium hydroxyapatite. After the core-shell structure calcium hydroxyapatite microsphere composite gel of the present application is implanted, calcium hydroxyapatite first contacts human tissues and is degraded into calcium ions and phosphate ions, stimulates collagen production and carries out tissue remodeling; then the biodegradable polymer is also metabolically degraded; and the degradation rate of calcium hydroxyapatite can control the exposure rate of the polymer microspheres, so that a long-term plumping filling effect is achieved; the gel has suitable viscoelasticity, can uniformly suspend the composite microspheres, and after injection into the human body, the microspheres are also uniformly dispersed in the gel.

The application belongs to the technical field of medicines, and particularly relates to application of alpha-asarone in preparation of a medicine for treating allergic rhinitis. The application aims at the problems of single drug target, prominent safety hazards and inability to block pathological progress from the root in the existing medicines for treating allergic rhinitis, takes alpha-asarone as an active ingredient, inhibits excessive activation of an inflammation pathway by activating an Nrf2 / HO-1 signal axis, and bidirectionally regulates expression balance of GPX4 and ACSL4 to inhibit ferroptosis and damage of a nasal epithelial barrier. Animal experiments prove that the alpha-asarone can significantly reduce allergic behaviors of model mice, relieve inflammation of nasal mucosa, reverse tissue remodeling, has high safety, and can be prepared into oral or nasal preparations, and provides a new treatment scheme with multiple target points for allergic rhinitis.

The invention relates to the field of microorganisms, and discloses a bifidobacterium longum BN-BB01 strain and application thereof in improvement of helicobacter pylori infection. The preservation number of the bifidobacterium longum BN-BB01 provided by the invention is CGMCC No.34432, and the bifidobacterium longum BN-BB01 can inhibit the activity of urease and the colonization and reproduction of helicobacter pylori, and also can regulate intestinal metabolism, so that the content of beneficial fatty acids in intestinal tracts is increased, and the content of corrupted fatty acids is remarkably reduced. Besides, the complete living bacteria body of the bifidobacterium longum also has a tissue remodeling capability, can specifically reverse gastric mucosa fibrosis caused by helicobacter pylori infection, and provides a new treatment approach for solving intestinal barrier and gastric mucosa structure damage caused by helicobacter pylori infection.

The invention relates to a fusion polypeptide for diabetes wound repair and a pharmaceutical composition thereof, and discloses a sequence design and a preparation method of the fusion polypeptide FP-DW01-Chol, and a temperature-sensitive hydrogel composition containing the polypeptide and MitoQ. The fusion polypeptide contains a TREM2 agonist domain, an AGE-RAGE blocking domain, an MMP9 recognition cleavage site, an Angiopoietin-2 mimic peptide fragment and a cholesterol modification terminal, and can activate anti-inflammatory polarization of macrophages, block a chronic inflammation pathway and respond to a wound enzyme environment to release an angiogenesis promoting fragment. The pharmaceutical composition takes poloxamer 407 / 188 as a temperature-sensitive carrier, realizes cooperative delivery of polypeptide and MitoQ, and has the advantages of slow release, skin retention and stability. In-vitro and db / db mouse model experiments prove that the composition can remarkably promote high-glucose damaged cell activity recovery, inhibit inflammatory factor release, accelerate wound closure, promote angiogenesis and tissue remodeling, provides a multi-mechanism synergistic and local long-acting treatment scheme for diabetic refractory wounds, and has important clinical transformation value.

The invention discloses composite hydrogel for promoting healing of chronic wound surfaces of diabetes and a preparation method of the composite hydrogel. The method comprises the following steps: (1) preparing a black phosphorus nanosheet BPNs suspension; (2) preparing aminated polyethylene glycol modified BPNs; (3) preparing methacrylated gelatin powder; and (4) preparing the composite hydrogel for promoting the healing of the chronic wound of diabetes mellitus. According to the preparation method, aminated polyethylene glycol is loaded on black phosphorus nanosheets in an electrostatic self-assembly action mode, the composite particles are excellent in antioxidant stability, and the loading capacity is stable and controllable; polyphosphates released by photo-thermal excitation response are used as biological energy precursors, in-situ regeneration of intracellular adenosine triphosphate is driven through adenylate kinase mediated phosphoryl transfer reaction, and energy metabolism disorder of a diabetes wound microenvironment is relieved fundamentally, so that migration of damaged cells, endothelial vascularization and tissue remodeling are promoted synergistically, and the wound healing effect is improved. The chronic wound healing is accelerated.

The present invention relates to a metal-organic framework for inhibiting the activity of M2 macrophages, and a pharmaceutical composition comprising same, wherein the metal-organic framework of the present invention is non-toxic to cells and can exhibit an effect of inhibiting the activity of M2 macrophages. More specifically, the metal-organic framework of the present invention can be provided as an anticancer composition for tumor-related macrophage-mediated diseases, particularly solid cancer, through the inhibition of M2 macrophages capable of increasing the expression of genes associated with parasite invasion, tissue remodeling, and tumor proliferation (immunomodulatory function), and can also be provided as a pharmaceutical composition for treating chronic infectious diseases, liver cirrhosis, obesity-related metabolic diseases, scar formation and idiopathic lung diseases.

A system for wound repair, coping with complex "inflammation storm" microenvironment, and double challenge of infection and inflammation, meets clinical needs. By loading plant-derived exosomes with scaffold characteristics of acellular matrix, a bioactive nanofiber dressing is constructed, which has physical protection and high porosity characteristics. Mechanism research shows that the system can continuously release by down-regulating pro-inflammatory cytokines to reshape the immune microenvironment, while showing strong broad-spectrum antibacterial activity against staphylococcus aureus, escherichia coli and pseudomonas aeruginosa. In addition, angiogenesis is significantly promoted and epithelial regeneration is accelerated through the HIF-1ɑ / VEGF pathway. In vivo evaluation confirms that compared with the commercial treatment scheme, the scheme of the present application can significantly improve the healing effect of burn wounds and achieve better tissue remodeling, providing a cost-effective solution for the management of severe burns.

The invention provides a recombinant collagen-polysaccharide dressing and a preparation method thereof. The dressing comprises recombinant humanized III-type collagen doped with 5-20% of VII-type or I-type collagen, and sodium hyaluronate, modified chitosan, a humectant and an auxiliary agent, the collagen is partially PEGylated and forms a layered network with the polysaccharide; the inner layer is collagen-HA-sacrificial network gel, and anti-fibrosis lipidosome is encapsulated so as to realize short-term release and fitting repair; the outer layer is a modified chitosan-HAMA / PEG film forming layer, has relatively high crosslinking density and slow degradation performance, provides mechanical support, has interfaces connected through hydrolyzable Schiff-base or ester bonds, and is self-dissociated within 7-10 days to promote tissue remodeling, and the dressing has good wettability, film forming-gel matching performance and long-acting stability.

The present invention relates to a peptide specifically activating signal transduction by targeting fibroblast growth factor receptor (FGFR), an FGFR agonist comprising the peptide, a pharmaceutical composition for preventing or treating diseases associated with decreased FGFR activity, and a cosmetic composition. An FAP1 peptide according to the present invention is a potent FGFR-activating peptide, which exhibited an effective concentration similar to that of bFGF protein, and showed the ability to promote wound healing and support tissue remodeling in vivo. Considering specificity to FGFR and the ability to promote wound healing , FAP1 can be used as a cost-effective alternative to the bFGF protein in therapeutic fields.

The present application relates to the technical field of intelligent medical monitoring, in particular to a burn wound healing process real-time monitoring method and system, comprising the following steps: collecting oxygen saturation data to construct a microcirculation blood flow feature set, performing texture tracking on a wound image to construct a global deformation vector field, fitting an edge line and combining the deformation field to obtain a net proliferation migration vector field, constructing a recursive feature matrix and calculating a laminar flow property and a capture time index, and outputting an evaluation result, in the present application, by combining microcirculation blood flow features and deformation field mapping, background motion interference is eliminated, net proliferation migration behavior is accurately quantified, a recursive feature matrix is constructed by mapping time series signals to phase space, laminar flow property and capture time index in state evolution are identified, multi-dimensional state determination is performed by fusing physiological blood flow parameters and morphological contraction coefficients, non-contact objective quantitative analysis of the healing process is realized, multi-dimensional pathological grading standards are established, and the dynamic trend of tissue remodeling is accurately reflected.

Systems and methods for remodeling of tissue, such as heart tissue. In some configurations, the systems and methods are directed toward remodeling of the mitral valve of a patient. The systems and methods can include a first tissue anchor, a second tissue anchor, a suture that extends between the tissue anchors, and a suture lock that secures the suture relative to at least one of the tissue anchors or fixes a length of the suture. The systems and methods can also include a suture trimmer that can trim an excess portion of the suture. In some configurations, the suture lock is reversible to allow for iterative adjustments of the remodeling.

The invention relates to the technical field of biological medicine. The invention provides a poria peel triterpene modified product-sodium alginate hydrogel dressing with a stage specific repair function as well as a preparation method and application of the poria peel triterpene modified product-sodium alginate hydrogel dressing. Three kinds of poria peel triterpene differentiation modified products (PCTT / SD, PCNT / SD and PCWT) are obtained through a solid dispersion technology or a salt forming technology, and after being loaded on hydrogel, the three kinds of poria peel triterpene differentiation modified products show clear and complementary stage specific treatment advantages in the complex wound healing process: PCNT / SD / Gel strongly regulates and controls early inflammation and accelerates initial repair; pCTT / SD / Gel significantly promotes synthesis and deposition of collagen in the middle stage; and the PCWT / Gel efficiently drives later epithelization, angiogenesis and tissue remodeling. Accurate time sequence regulation and control of the wound healing process are achieved, an innovative treatment strategy is provided for refractory wounds such as diabetic foot ulcer, and the additional value of the poria cocos peel by-product is remarkably increased.

The application discloses a short peptide for TRPM7 channel, a vaccine and pharmaceutical application of the short peptide for preventing and treating atrial fibrillation, and belongs to the technical field of biological medicine. The short peptide can be coupled with a carrier KLH by a glutaraldehyde coupling method to prepare a conjugate, and the conjugate is supplemented with an adjuvant to form a vaccine. The vaccine can induce the body to produce high-specificity and high-titer antibodies through active immunization, the antibodies can block the TRPM7 channel, inhibit calcium influx of atrial muscle cells and atrial fibroblasts, reduce calcium overload of cytoplasm, inhibit atrial electrical remodeling and tissue remodeling, and prevent and treat atrial fibrillation. The application provides a pharmaceutical composition containing the short peptide, the conjugate and the adjuvant, and a polyclonal antibody obtained by immunizing a non-human animal with the vaccine. Compared with existing chemical drugs, the application has the advantages of high targeting, long-acting, good safety, low price and the like, provides a new active immunotherapy strategy for atrial fibrillation patients, and has a wide clinical transformation prospect.

The application discloses a kind of active delivery system of load ABPC-EVs and its application in the preparation of preventing or treating hyperplastic scar, belong to the field of biological medicine technology.The active delivery system of load ABPC-EVs described above is composed of ABPC-EVs and drug delivery system.The application utilizes ABPC-EVs as core biological active substance, by constructing active delivery system, is applied to the treatment and prevention of hyperplastic scar, can accurately intervene the abnormal metabolism of fibroblast, inhibits the pathological accumulation of collagen fiber, breaks through the dense tissue barrier caused by hyperplastic scar, realizes the accurate delivery of drug, and then realizes the physical flat of hyperplastic scar, color improvement and physiological reconstruction, solve the problems, such as lack of accurate physical-biological synergistic intervention, poor tissue remodeling quality and low bioavailability, in the prior art for treating hyperplastic scar, has great clinical application prospect.

The present disclosure relates to the use of non-coding circular RNA circRNA_00285 in the preparation of a drug for promoting wound healing. It also relates to an expression vector in which the non-coding circular RNA circRNA_00285 is inserted, and when the expression vector is transfected into the cells of animal tissues, the inserted non-coding circular RNA circRNA_00285 can be overexpressed in the cells of animal tissues. A method for promoting wound healing, the method comprising: applying a product containing non-coding circular RNA circRNA_00285 at the wound site of an animal, and overexpressing the non-coding circular RNA circRNA_00285 in the cells of animal tissues. By overexpressing the non-coding circular RNA circRNA_00285 in the skin cells of the animal wound, the proliferation and migration of cells can be promoted, and the expression of inflammatory factors can be inhibited, promoting tissue remodeling and improving the healing speed of the wound.

This invention provides a FAP-targeted engineered exosome for treating hypertrophic scars, its preparation method, and its application, belonging to the field of biopharmaceutical manufacturing technology. After co-incubation with an ferroptosis inducer, the FAP-targeting small molecule ligand SUC-Lys(Ac)-PEG3-UAMC1110 is covalently linked to the exosome membrane surface using an EDC / NH-mediated amide bond coupling strategy to obtain engineered exosomes. These engineered exosomes are then used to prepare microneedle patches. The microneedle patches allow the engineered exosomes to accumulate at the scar site and preferentially enter FAP-highly expressed scar fibroblasts, inhibiting their abnormal proliferation, migration, and pro-fibrotic phenotype, reducing collagen deposition, and promoting hypertrophic scar tissue remodeling. This invention combines the advantages of strong targeting, low off-target toxicity, minimally invasive drug delivery, sustained local retention, and stable efficacy, making it suitable for preparing drugs to treat or improve hypertrophic scars, and possessing good clinical translational potential.

Tissue derived porous matrices for treating wounds are provided, as well as methods for making and using them. The tissue derived porous matrices comprise processed tissue of any of several types, such as dermis, adipose, etc., and have a plurality of interconnected pores which allow fluid flow through the matrices. The tissue derived matrices are biocompatible resorbable matrices which remodel with native tissue and facilitate and enhance cell infiltration and tissue ingrowth into the matrices, thereby enhancing wound healing and tissue remodeling when implanted into a patient. The tissue derived matrices are useful for treating wounds and, due to their biocompatibility and remodeling properties, they provide the option of removing or leaving in place one or more portions of the matrices which remain unincorporated some period of time after implanting, thereby avoiding the need to repeatedly revisit the treatment site to remove previously implanted matrices.

The invention discloses application of an ADAM8 gene and / or ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp and the medicine, and relates to the technical field of biological medicines. According to the application of the ADAM8 gene and / or the ADAM8 protein in preparation of a medicine for treating chronic sinusitis with nasal polyp, the ADAM8 gene and / or the ADAM8 protein are / is used as a treatment target. The research finds that the gene and protein expression level of ADAM8 are obviously up-regulated in ECRSwNP and NECRSwNP and are mainly distributed in inflammatory cells of epithelium and below the epithelium, which prompts that ADAM8 may be a key pathogenic factor in CRSwNP pathogenesis. By specifically inhibiting the activity of ADAM8, nasal polyp-like lesions can be remarkably relieved, infiltration of eosinophilic granulocytes, neutrophil granulocytes and other inflammatory cells can be reduced, key inflammatory signal pathways can be inhibited, collagen deposition and metal matrix protease expression can be reduced, then inflammatory response and a tissue remodeling process can be effectively relieved, and the application of ADAM8 in treatment of nasal polyp-like diseases can be promoted. The scientificity and clinical application prospect of the ADAM8 as a treatment target are verified.

The application belongs to the technical field of hydrogel microneedles, and relates to a hydrogel microneedle and a preparation method thereof, and the preparation method comprises the following steps: placing a methacrylated chitosan solution in a centrifugal tube, adding a photoinitiator, vortexing and ultrasonicating until the photoinitiator is completely dissolved to obtain a hydrogel microneedle filling solution; and taking the hydrogel microneedle filling solution and injecting the hydrogel microneedle filling solution into a PDMS microneedle mold, centrifuging, irradiating with an ultraviolet lamp and drying.The hydrogel microneedle prepared from methacrylated chitosan has superior performance in wound closure, re-epithelialization and hair follicle formation, and the hydrogel microneedle is combined with a rhodioside drug depot to construct a transdermal drug delivery system, the drug delivery system has high drug loading and no polymer deposition, can efficiently transdermally deliver rhodioside, promotes wound closure and tissue remodeling, and provides a potential strategy for wound treatment.

This invention discloses a pH / ROS-responsive multifunctional hydrogel loaded with ruthenium dioxide nanoparticles, its preparation method, and its applications. Belonging to the field of biomedical materials and drug delivery technology, it utilizes Schiff base reactions and dynamic borate ester reactions to load RuNPs and form a hydrogel (G@Ru) to address several key factors: i) RuNPs exhibit inherent antibacterial activity and ROS scavenging, alleviating inflammation and promoting tissue regeneration, thus accelerating the healing of MRSA-infected diabetic wounds; ii) A ROS / pH dual-responsive hydrogel matrix (Gel) is synthesized as a smart drug carrier, intelligently releasing RuNPs using the pH-responsive activity of the Schiff base and the ROS-responsive activity of the dynamic borate ester; iii) RuNPs reduce inflammation levels while regulating macrophage polarization, promoting angiogenesis and cell proliferation; iv) G@Ru accelerates tissue remodeling and repair through collagen deposition, achieving faster recovery with minimal scarring.

The application relates to the technical field of cell biology, and particularly relates to application of a skin organoid conditioned medium in promoting repair of acute skin damage tissue, to a human skin organoid in-vitro model, to collection of a skin organoid conditioned medium (SOCCM) cultured for 6-8 days, enrichment of a variety of secretory factors related to skin repair, inflammation control and angiogenesis in the skin organoid conditioned medium, formation of a characteristic secretome, in-vivo and in-vitro experiment verification that the skin organoid conditioned medium can significantly promote fibroblast migration, vascular endothelial cell lumen formation, accelerate acute skin damage wound closure, promote collagen ordered deposition and tissue remodeling, and improve skin damage repair quality. The application avoids tumorigenic and immunological rejection risks of the organoid / stem cell transplantation, provides a new treatment strategy for repair of the acute skin damage, and can also be applied to repair of chronic non-healing wounds and repair of skin light damage and the like.

The application provides a traditional Chinese medicine medicinal liquor for treating bone disease pain, which is prepared from the following raw medicinal materials and base liquor: 20-40 grams of rhabdophis nidorus, 10-30 grams of chonglicania, 10-30 grams of safflower, and 8-22 grams of radix angelicae pubescentis; the base liquor is pure grain liquor with a volume fraction of 53 degrees, and the ratio of the total weight of the raw medicinal materials to the volume of the base liquor is 1 gram: 15-18 milliliters; the application discards the drawbacks of traditional medicinal liquor with multiple components, and only uses four kinds of medicines to precisely attack pathological targets, especially creatively introduces safflower, aims at the medical problem that the annulus fibrosus of intervertebral disc lacks blood vessels and is difficult to heal itself, improves local microcirculation to induce new blood vessels to grow in, and realizes tissue remodeling and physiological healing of the ruptured annulus fibrosus for the first time.